Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder

Completed · Phase 3

Conditions studied: Depressive Disorder

In brief

The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.

Key facts

Study ID

NCT00036309

Run by

Eli Lilly and Company

Starts

2002-05-01

Expected to finish

2003-07-01

Last updated by the study team

2006-07-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed the informed consent
• Meet criteria for major depressive disorder without psychotic features.
• Have a level of understanding sufficient to provide informed consent and to communicate with the investigator and site personnel.
• Have had at least one other major depressive episode prior to the one being experienced at study entry.
• You are reliable and agree to keep all appointments for clinic visits, tests and procedures required by the protocol.

You may not qualify if…

• You have had treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry.
• Any women who are pregnant or breast feeding.
• If you have any serious medical illnesses other than major depressive disorder.
• If you have previously participated in a clinical trial for duloxetine.
• Any previous or current diagnosis of bipolar, schizophrenia, or other psychotic disorders.

Where it is running

• For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559) — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.